Zealand Pharma (ZEAL) Stock Plunges 12% Despite Promising Obesity Drug Weight Loss Results

Key Takeaways

• Zealand Pharma experienced a sharp 12% decline in share value Thursday following the publication of advanced clinical trial data.
• The SYNCHRONIZE-2 Phase III study evaluated survodutide in individuals living with obesity and concurrent type 2 diabetes.
• Participants receiving the treatment experienced weight reduction of up to 13.1% compared to 3.1% in the control group.
• Approximately 18% of survodutide recipients discontinued participation because of digestive system-related adverse reactions.
• The drug is licensed to Boehringer Ingelheim by Zealand, with Boehringer managing worldwide clinical development.

Shares of Zealand Pharma (ZEAL) experienced a significant decline of up to 12% Thursday following the public disclosure of clinical trial data for survodutide, the company’s investigational obesity medication.

Zealand Pharma A/S, ZEAL

The data emerged from the SYNCHRONIZE-2 Phase III clinical investigation, which examined survodutide’s performance in adult participants who were either obese or overweight and simultaneously managing type 2 diabetes.

Study participants administered survodutide demonstrated average weight reductions reaching 13.1%. Meanwhile, individuals receiving placebo treatment showed only a 3.1% decrease.

The clinical investigation spanned 76 weeks and enrolled 755 adult participants. They received weekly subcutaneous administrations of either 3.6 mg or 6 mg survodutide doses, or an inactive placebo.

Understanding the Market Reaction

While the efficacy data demonstrated compelling weight reduction outcomes, market participants concentrated their attention elsewhere: the treatment discontinuation statistics.

Approximately 18% of individuals receiving survodutide withdrew from the study due to gastrointestinal adverse events. By comparison, merely 1.2% of placebo recipients discontinued for similar reasons.

The adverse reactions reported encompassed nausea, vomiting, diarrhea, and constipation. Zealand characterized the majority of these events as mild to moderate in severity.

The bulk of participant withdrawals occurred during the dosage titration period, when patients underwent gradual increases to reach their target therapeutic dose.

Close to 80% of survodutide-treated individuals successfully achieved a minimum of 5% body weight reduction. Among placebo recipients, this proportion stood at 32.7%.

Beyond weight loss, the medication demonstrated improvements in HbA1c, a critical indicator of glycemic regulation. Reductions reached up to 1.21 percentage points from an initial baseline measurement of 7.4%.

The control group registered only a 0.03 percentage-point decrease in HbA1c values. The investigation successfully achieved both primary endpoints.

Development Timeline and Next Steps

Survodutide operates through a dual mechanism of action, simultaneously engaging both glucagon and GLP-1 receptor pathways.

Zealand Pharma has granted licensing rights for the compound to Boehringer Ingelheim, which oversees all aspects of global clinical advancement and future commercialization efforts.

The medication currently lacks regulatory authorization in any jurisdiction. Its safety profile and therapeutic benefit remain under regulatory evaluation.

Boehringer Ingelheim is conducting an additional Phase III investigation designated SYNCHRONIZE-T2D. This complementary study focuses specifically on survodutide’s impact on glycemic management in individuals with type 2 diabetes.

Data from SYNCHRONIZE-CVOT, a cardiovascular outcomes investigation, is anticipated to become available before year-end. These findings may prove influential in shaping regulatory assessments and physician perspectives regarding the drug’s extended safety profile.

A supplementary investigation, SYNCHRONIZE-1, examined body composition changes in 75 individuals without type 2 diabetes. Findings indicated that muscle tissue accounted for no more than 10% of overall tissue reduction throughout the treatment period.

Complete SYNCHRONIZE-2 findings were unveiled at the European Association for the Study of Diabetes annual scientific meeting. Simultaneously, the results appeared in The New England Journal of Medicine on the identical date.